MONDAY, April 8 (HealthDay News) -- A drug called amiodarone
that's widely used to treat heartbeat irregularities might raise a
patient's risk of cancer, Taiwanese researchers report.
The risk, which the researchers termed "borderline significantly
increased," is more pronounced in men and patients who take high
doses of the drug, according to the study, which was published
online April 8 in the journal
"When prescribing amiodarone, doctors need to keep in mind that this medication may increase cancer risk," said lead author Dr. Vincent Yi-Fong Su, from the Taipei Veterans General Hospital. "We suggest that cancer events should be routinely reported in future amiodarone trials, and further observational research is necessary."
Patients taking the drug, however, shouldn't fear they'll get
cancer, one expert said.
"Amiodarone is among the most effective antiarrhythmic medications available," said Dr. Gregg Fonarow, a spokesman for the American Heart Association and professor of cardiology at the University of California, Los Angeles. "Well-controlled clinical trials have not demonstrated a significant increase in cancer with use of this medication."
The current study, called an observational study, doesn't prove
that amiodarone causes cancer, only that an association was found
between people taking the drug and cancer.
Many risk factors for heart disease and arrhythmia are also risk
factors for cancer, Fonarow said. The findings of this study
comparing those treated with amiodarone to the general population
are most likely explained by selection of patients and other
factors that weren't taken into account, he said.
"These findings should not be a concern to patients taking amiodarone," Fonarow said.
Amiodarone (sold as Cordarone and Pacerone) is commonly
prescribed to prevent life-threatening arrhythmias, such as
ventricular tachycardia or ventricular fibrillation, both of which
can lead to cardiac arrest.
Ventricular tachycardia is a very rapid beating of the upper
chambers of the heart. When these chambers don't beat in the
correct order, the condition is called ventricular fibrillation.
These problems prevent blood from being pumped properly and can
cause the heart to stop beating altogether.
Amiodarone breaks down slowly, so large amounts can remain in
soft tissues when the drug is taken for a long time. This might
explain its association with cancer, the researchers said. Earlier
studies have shown an association between amiodarone and cancer
risk, but this is the largest study to date to show a link, they
For the study, Su's team followed more than 6,400 patients
taking amiodarone for almost three years. Among these patients, 280
Men taking high doses of the drug had a 46 percent higher chance
of developing cancer than those who were neither male nor taking
large doses. Anyone taking high doses had nearly twice the risk of
cancer compared with people taking low doses, the researchers
Cancers of the digestive system, lung, liver, colon, ovaries and
prostate were among the cancers associated with amiodarone, the
For more information on amiodarone, visit the
U.S. National Library of Medicine.
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.